Translational services are dedicated to understanding candidate therapeutics and generating clinically relevant data using fresh human samples from both healthy and diseased populations.
With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.
Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.
We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.
Synexa Life Sciences is a global provider of biomarker and bioanalytical services, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.
With decades of experience in biomarker strategies and assay development, our biomarker panels enhance decision-making in all stages of therapeutic clinical development.
Synexa delivers advanced LC-MS/MS and LC-UV bioanalysis solutions from a custom-built 16,500 sqft UK facility near Manchester Airport.
Immunoassays are a fundamental tool for the development of large-molecule biotherapeutics, enabling sensitive and specific quantification of drug levels in clinical samples.
Flow Cytometry is core to Synexa’s positioning as a biomarker expert. We provide key expertise in the development and validation of complex assays, encompassing multimer staining, phospho-flow and target engagement assays.
The ELISpot assay precisely detects and quantifies antigen-specific immune responses at the single-cell level, providing insights into immune activity across various disease settings.
Formulation analysis is an essential support service for GLP toxicology studies and is often advisable on non-GLP studies when the accuracy of dosing solutions is critical.
Synexa specialises in biomarker and bioanalytical services which can be specifically tailored to suit both the modality of the therapeutic and the disease area of focus. Autoimmune conditions are highly heterogenous, affecting numerous cell types, molecular pathways and tissues, necessitating multi-pronged approaches integrating technology platforms including targeted genetic analysis, soluble biomarkers and flow cytometry.
Synexa’s expertise in the field of immunology and immune-based analytical technologies makes us the perfect partner in advancing oncology therapeutic pipelines. We use innovative approaches and validated platforms to answer client-specific questions for quality, clinically-relevant data.
Accelerate vaccine development and evaluation with our comprehensive suite of bioanalytical services, supporting safety, immunogenicity, and efficacy assessments for a wide range of vaccine candidates.
Robust analytical solutions for biosimilar development, offering comparative bioanalysis, potency assays, and structural characterisation to ensure similarity to reference biologics and meet regulatory requirements.
Discuss biomarker and bioanalytical solutions to accelerate your therapeutic pipeline
